Cardiff University | Prifysgol Caerdydd ORCA
Online Research @ Cardiff 
WelshClear Cookie - decide language by browser settings

Browse by Current Cardiff authors

Number of items: 6.

Davison, Zoë, Nicholson, Robert I., Hiscox, Stephen ORCID: and Heard, Charles M. ORCID: 2018. Co-administration of fish oil with signal transduction inhibitors has anti-migration effects in breast cancer cell lines, in vitro. The Open Biochemistry Journal 12 (1) , pp. 130-148. 10.2174/1874091X01812010130

Agrawal, Amit, Robertson, John F.R., Cheung, Kwok L., Gutteridge, Eleanor, Ellis, Ian O., Nicholson, Robert I. and Gee, Julia M.W. ORCID: 2016. Biological effects of fulvestrant on estrogen receptor positive human breast cancer: short, medium and long-term effects based on sequential biopsies. International Journal of Cancer 138 (1) , pp. 146-159. 10.1002/ijc.29682

Stone, Andrew, Zotenko, Elena, Locke, Warwick J., Korbie, Darren, Millar, Ewan K. A., Pidsley, Ruth, Stirzaker, Clare, Graham, Peter, Trau, Matt, Musgrove, Elizabeth A., Nicholson, Robert I., Gee, Julia M. W. ORCID: and Clark, Susan J. 2015. DNA methylation of oestrogen-regulated enhancers defines endocrine sensitivity in breast cancer. Nature Communications 6 , 7758. 10.1038/ncomms8758

Gee, Julia Margaret Wendy ORCID:, Goddard, Lindy, Mottram, Huw James, Burmi, Rajpal, Pumford, Sara L., Dutkowski, Carol M., Barrow, Denise, Hutcheson, Iain Robert, Nicholson, Robert Ian, Ellis, Ian O. and Elvin, Paul 2014. Increased Ret signalling and impact of vandetanib in acquired tamoxifen resistant breast cancer. Cancer Research 74 (19) , 738. 10.1158/1538-7445.AM2014-738

Jones, Helen E., Gee, Julia Margaret Wendy ORCID:, Hutcheson, Iain Robert and Nicholson, Robert Ian 2006. Growth factor pathway switching: implications for the use of gefitinib and trastuzumab. Breast Cancer Online 9 (7) , e27. 10.1017/S1470903106005451

Jones, Helen E., Barrow, Denise, Dutkowski, Carol, Goddard, Lindy, Smith, Christopher, Harper, Maureen E. and Nicholson, Robert Ian 2001. Effect of an EGF-R selective tyrosine kinase inhibitor and an anti-androgen on LNCaP cells: Identification of divergent growth regulatory pathways. The Prostate 49 (1) , pp. 38-47. 10.1002/pros.1116

This list was generated on Sun Feb 25 05:31:00 2024 GMT.